Publications

Academic publications

2021

  • Ejegod DM, Pedersen H, Pedersen BT, Jonassen CM, Lie AK, Hulleberg LS, Arbyn M, Bonde J. Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program. Am J Clin Pathol. 2021 Sep 21:aqab138. doi: 10.1093/ajcp/aqab138
  • Obermueller T, Hautekiet J, Busto MP, Reynders D, Belgioia L, Cats A, Gilbert DC, Koerber SA, Mai S, Meulendijks D, Rödel F, Yhim H, Hetjens S, Weiß C, Rasmussen CL, Urbute A, Verdoodt F, Kjaer SK, Reuschenbach M, Goetghebeur E, von Knebel Doeberitz M, Arbyn M, Priggea E. Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis. Eur J Cancer 2021, 157; 165-178 doi: doi.org/10.1016/j.ejca.2021.07.041
  • Yuill S, Velentzis LS, Smith M, Egger S, Wrede CD, Bateson D, Arbyn M, Canfell K. The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes. Hum Vaccin Immunother 2021. Oct 3;17(10):3562-3576. doi: 10.1080/21645515.2021.1936860.
  • Strojan Fležar M, Nedelko N, Poljak M, Oštrbenk Valencak A, Gutnik H. Stratified Mucin-Producing Intraepithelial Lesion (SMILE) of the Uterine Cervix: High-Risk HPV Genotype Predominance and p40 Immunophenotype. Cells 2021, 10, 2039.doi: 10.3390/cells10082039.
  • Gray P, Kann H, Pimenoff VN, Eriksson T, Luostarinen T, Vänskä S, Surcel HM, Faust H, Dillner J, Lehtinen M. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. PLoS Med. 2021 Jun 7;18(6):e1003588. doi: 10.1371/journal.pmed.1003588.
  • Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, Baussano I. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health. 2021 Jul;6(7):e510-e521. doi: 10.1016/S2468-2667(21)00046-3.
  • Suomenrinne-Nordvik A, Vänskäa S. The confounding effect of multi-type human papillomavirus infections on type-specific natural history parameter identification. Epidemics Volume 36, September 2021, 100468 doi.org/10.1016/j.epidem.2021.100468
  • Oštrbenk Valenčak A, Bertram A, Gröning A, Poljak M. Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting.Journal of Clinical Virology Volume 140, July 2021, 104851. doi: doi.org/10.1016/j.jcv.2021.104851
  • Arbyn M, Simon M, Peeters E, Meijer CJLM, Berkhof J, Cuschieri K, Bonde J, Oštrbenk Valenčak A, Zhao F-H , Rezhake R, Gultekin M, Dillner J, de Sanjosé S, Canfell K, Hillemanns P, Almonte M, Xu L, Wentzensen N, Poljak M. 2020 List of human papillomavirus assays Suitable for primary cervical cancer screening. Clin Microbiol Infect 2021 May 8;S1198-743X(21)00219-6. doi: 10.1016/j.cmi.2021.04.031
  • Dhillona SK, Oštrbenk Valenčak A, Xu L, Poljak M, Arbyn M, Clinical and analytical evaluation of the Alinity m HR HPV 2 assay within the VALGENT-3 framework. J Clin Microbiol. 2021 Mar 17;JCM.00286-21. doi: 10.1128/JCM.00286-21
  • Vink FJ, Dick S, Heideman DAM, de Strooper L, Steenbergen RDM, Lissenberg-Witte BLW, DNTP group, Floore A, Bonde JH, Oštrbenk Valenčak A, Poljak M, Petry KU, Hillemans P, van Trommel NE, Berkhof J, Bleeker MCG, Meijer CLJM, Classification of high‐grade CIN by p16ink4a, Ki‐67, HPV E4 and FAM19A4/miR124‐2 methylation status demonstrates considerable heterogeneity with potential consequences for management. Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33566.
  • Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, Kelly D, Poljak M, Bergeron C, Ritchie D, Schmidt D, Kyrgiou M, Van den Bruel A, Bruni L, Basu P, Bray F, Weiderpass E. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 2021 Jan 15;148(2):277-284. doi: 10.1002/ijc.33189.

2020

  • Inturrisi F, Bogaards JA, Heideman DAM, Meijer CJLM, Berkhof J. Risk of cervical intraepithelial neoplasia grade 3 or worse in HPV-positive women with normal cytology and five-year type concordance: a randomized comparison. Cancer Epidemiol Biomarkers Prev 2020 Dec 8 doi:10.1158/1055-9965.EPI-20-1336
  • Robles C, Bruni L, Acera A, Riera JC, Prats L, Poljak M, Mlakar J, Ostrbenk Valencak A, Eriksson T, Lethinen M, Louvanto K, Hortlund M, Dillner J, Faber MT, Munk C, Kjaer SK, Petry KU, Denecke A, Xu L, Arbyn M, Cadman L, Cuzick J, Dalstein V, Clavel C, de Sanjosé S, Bosch FX. Determinants of Human Papillomavirus Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. Am J Prev Med 2020 Dec 24;S0749-3797(20)30434-7. doi: 10.1016/j.amepre.2020.08.032.
  • Tagliabue M, Mena M, Maffini F, Gheit T, Quirós Blasco B, Holzinger D, Tous S, Scelsi D, Riva D, Grosso E, Chu F, Lucas E, Ridder R, Rrehm S, Bogers JP, Lepanto D, Lloveras Rubio B, Kumar RV, Gangane N, Clabero O, Pawlita M, Anantharaman D, Pillai MR, Brennan P, Sankaranarayanan R, Arbyn M, Lombardi F, Taberna M, Gandini S, Chiesa F, Ansarin M, Alemany L, Tommasino M, Chiocca S and the HPV-AHEAD Study Group. Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study. Cancers 2020, 12(12), 3567; https://doi.org/10.3390/cancers12123567.
  • Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, Kim J, Poljak M, Nieminen P, Sasieni P, Kesic V, Cuzick J, Gultekin M. Cervical screening: ESGO- EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020 Aug;123(4):510-517. doi: 10.1038/s41416-020-0920-9.
  • Arbyn M, Bruni L, Kelly D, Basu P, Poljak M, Gultekin M, Bergeron C, Ritchie D, Weiderpass E. ‘Tackling Cervical Cancer in Europe amidst the COVID-19 Pandemic’. The Lancet Public Health 5, no. 8 (1 August 2020): e425.
  • Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A, Harjula K, Heikkila K, Hokkanen M, Huhtinen L, Ikonen M, Karttunen H, Nummela M, Söderlund-Strand A, Veivo U, Dillner J, Elfstöm M, Nieminen P, Lehtinen M. Baseline findings and safety of of infrequent of frequent screening of human papillomavirus vaccinated women. International Journal of Cancer. 2020 Jul 15;147(2):440-447. doi: 10.1002/ijc.32802.
  • Bray F, Laversanne M, Weiderpass E, Arbyn M. ‘Geographic and Temporal Variations in the Incidence of Vulvar and Vaginal Cancers’. International Journal of Cancer 147, no. 10 (2020): 2764–71. https://doi.org/10.1002/ijc.33055.
  • Arbyn M, Gondry J, Nieminen P. Long-term prediction of failure after treatment of cervical precancer. BJOG. 2020 Feb;127(3):388. doi: 10.1111/1471-0528.16023.
  • Ciavattini A, Delli Carpini G, Giannella L, Arbyn M, Kyrgiou M, Joura EA, Sehouli J, Carcopino X, Redman CW, Nieminen P, Cruickshank M, Gultekin M. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. Int J Gynecol Cancer. 2020 Aug;30(8):1097-1100. doi: 10.1136/ijgc-2020-001617.
  • Inturrisi F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, Ronco G, Meijer CJLM, Berkhof J. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. Int J Cancer. 2020 Jul 14. doi: 10.1002/ijc.33207.
  • Arbyn M, Rezhake R, Yuill S, Canfell K. Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. Br J Cancer. 2020 May;122(11):1577-1579. doi: 10.1038/s41416-020-0787-9.
  • Ejegod, Ditte Møller, Mona Hansen, Irene Kraus Christiansen, Helle Pedersen, Wim Quint, Lan Xu, Marc Arbyn, and Jesper Bonde. ‘Clinical Validation of the Cobas 4800 HPV Assay Using Cervical Samples in SurePath Medium under the VALGENT4 Framework’. Journal of Clinical Virology 128 (1 July 2020): 104336. https://doi.org/10.1016/j.jcv.2020.104336.
  • Peeters E, Cornet K, Devroey D, Arbyn M. ‘Efficacy of Strategies to Increase Participation in Cervical Cancer Screening: GPs Offering Self-Sampling Kits for HPV Testing versus Recommendations to Have a Pap Smear Taken - A Randomised Controlled Trial’. Papillomavirus Research 9. https://doi.org/10.1016/j.pvr.2020.100194. Corrigendum: doi: 10.1016/j.pvr.2020.100201
  • Xu L, Ostrbenk Valencak A, Poljak M, Arbyn M. Evalaution and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 framework. J Clin Microbiol 2020 May 26;58(6):e00234-20. doi: 10.1128/JCM.00234-20.
  • Urbute A, Rasmussen CL, Belmonte F, Obermueller T, Prigge E, Arbyn M, Verdoodt F, Kjaer S. Prognostic Significance of HPV DNA and p16 INK4a in Anal Cancer: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev 2020 Apr;29(4):703-710. doi: 10.1158/1055-9965.EPI-19-1259.
  • Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, Xu L, Arbyn M. ‘Commercially Available Molecular Tests for Human Papillomaviruses: A Global Overview’. Clinical Microbiology and Infection, 2 April 2020. https://doi.org/10.1016/j.cmi.2020.03.033.
  • Rezhake R, Chen F, Hu S, Zhao X, Zhang X, Cao J, Qiao Y, Zhao F, Arbyn M. ‘Triage Options to Manage High-Risk Human Papillomavirus-Positive Women: A Population-Based Cross-Sectional Study from Rural China’. International Journal of Cancer 147, no. 8 (2020): 2053–64. https://doi.org/10.1002/ijc.33001.
  • Nowakowski A, Arbyn M, Turkot MH, Wieszczy P, Milosz K, Kaminski M, Didkowska J, Bidzinski M, Oleszewski W, Wielgos M, Krzakowski M, Kuchar E, Walewski J. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. Eur J Cancer Prev 2020 Mar;29(2):157-164. doi: 10.1097/CEJ.0000000000000528.
  • Kalliala I, Athanasiou A, Veroniki AA, Galanti G, Efthimiou O, Raftis N, Bowden S, Paraskevaidi M, Aro K, Arbyn M, Bennet P, Nieminen P, Parakevaidis E, Kyrgiou M. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol 2020 Feb;31(2):213-227. doi: 10.1016/j.annonc.2019.11.004.
  • Arbyn M, Weiderpass E, Bruni L, de Sanjosé, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6.
  • Bonde JH, Pedersen H, Quint W, Xu L, Arbyn M, Ejegod DM. Clinical and Analytical Performance of the BC Onclarity HPV assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework. J Clin Microbiol . 2020 Jan 28;58(2):e01518-19. doi: 10.1128/JCM.01518-19.
  • Weyers S, Garland SM, Cruickshank M, Kyrgiou M, Arbyn M. ‘Cervical Cancer Prevention in Transgender Men: A Review’. BJOG: An International Journal of Obstetrics & Gynaecology (2020). https://doi.org/10.1111/1471-0528.16503.

Other publications